Update Regarding Variant Strains of SARS-CoV-2
The CDC has identified SARS-CoV-2 variants that have been determined to be variants of public health concern. Rheonix has conducted in silico analysis of the potential impact of these variants and has determined that they should not impact performance of the Rheonix COVID-19™ MDx assay.
|WHO Label||CDC Variant of Concern*||Also Known As||First Detected||Impact to Rheonix COVID-19™ MDx Assay|
|Alpha||B.1.1.7||20I/501Y.V1||United Kingdom||No impact|
|Beta||B.1.351||20H/501.V2||South Africa||No impact|
*Source: SARS-CoV-2 Variants of Concern | CDC
Rheonix continually monitors publicly available SARS-CoV-2 genetic sequences to identify the potential impact of variants on our assay performance.